SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)

• A. López-Pousa ^[3] ; J. Martin Broto ^[8] ; J. Martinez Trufero ^[4] ; I. Sevilla ^[5] ; C. Valverde ^[6] ; R. Alvarez ^[7] ; J. A. Carrasco Alvarez ^[9] ; J. Cruz Jurado ^[1] ; N. Hindi ^[8] ; X. Garcia del Muro ^[2]
  1. [1] Hospital Universitario de Canarias

     Hospital Universitario de Canarias

     San Cristóbal de La Laguna, España

     
  2. [2] Hospital Duran i Reynals

     Hospital Duran i Reynals

     Barcelona, España

     
  3. [3] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  4. [4] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  5. [5] Hospital Universitario Virgen de la Victoria

     Hospital Universitario Virgen de la Victoria

     Málaga, España

     
  6. [6] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  7. [7] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  8. [8] Hospital Virgen del Rocio, España
  9. [9] Hospital Universitario de Vigo, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 12 (December 2016), 2016, págs. 1213-1220
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Soft-tissue sarcomas are uncommon and heterogeneous tumors of mesenchymal origin. A soft-tissue mass that is increasing in size, greater than 5 cm, or located under deep fascia are criteria for suspicion of sarcoma. Diagnosis, treatment, and management should preferably be performed by a multidisciplinary team in reference centers. MRI and lung CT scan are mandatory for local and distant assessment. A biopsy indicating histological type and grade is needed previous to the treatment. Wide surgical resection with tumor-free tissue margin is the primary treatment for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not likely of being improved with reexcision. Neoadjuvant and adjuvant chemotherapy improve survival in selected cases, usually in high-grade sarcomas of the extremities. In the case of metastatic disease, patients with exclusive lung metastasis could be considered for surgery. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. New drugs have shown activity in second-line therapy and in specific histological subtypes.